Expressive

rs10490551 - EML4 - COX7A2L

Magnitude 4.5 · 1 study on file

Reported associations

  • Multi-ancestry genome-wide association analyses improve resolution of genes and pathways influencing lung function and chronic obstructive pulmonary disease risk - Unknown journal (n.d.) · Unknown authors · PubMed 36914875

    ABSTRACT: Lung-function impairment underlies chronic obstructive pulmonary disease (COPD) and predicts mortality. In the largest multi-ancestry genome-wide association meta-analysis of lung function to date, comprising 588,452 participants, we identified 1,020 independent association signals implicating 559 genes supported by ≥2 criteria from a systematic variant-to-gene mapping framework. These genes were enriched in 29 pathways. Individual variants showed heterogeneity across ancestries, age and smoking groups, and collectively as a genetic risk score showed strong association with COPD across ancestry groups. We undertook phenome-wide association studies for selected associated variants as well as trait and pathway-specific genetic risk scores to infer possible consequences of interve

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Exercise

  • Regular aerobic exercise for lung capacity Moderate

    Aerobic exercise improves respiratory fitness and may offset genetic predisposition to reduced FEV1

    150 minutes per week moderate-intensity aerobic activity

Lifestyle

  • Tobacco smoke and air pollution exposure High

    Smoke and pollution accelerate FEV1 decline; genetic predisposition to lower baseline function increases vulnerability

    Maintain smoke-free environment; limit outdoor activity during high air pollution days

Screening

  • Baseline spirometry and periodic lung function testing High

    Genetic variant associated with reduced FEV1; baseline assessment enables detection of accelerated decline

    Baseline spirometry at age 30-35, then every 2-3 years